RiverVest Venture Partners

RiverVest Venture Partners does not develop drugs directly but invests in and helps build early-stage biopharma and medical device companies. Its portfolio includes companies with programs ranging from pre-clinical to commercial stages. Several of its investments have resulted in successful exits via IPO or acquisition and led to the commercialization of products such as Lokelma™ for hyperkalemia and Margenza for breast cancer.

The firm has invested in over 55 companies and founded 15 since inception.

As of early 2025, it has made at least 140 investments with numerous successful exits.

Select notable products developed by its portfolio include Lokelma™ (hyperkalemia), Vfend® (fungal infections), Quinsair® (cystic fibrosis), Margenza® (breast cancer), Lutonix drug-coated balloon angioplasty system, Supera peripheral stent system, Emblem leadless defibrillator.

No direct clinical results are reported for the firm itself.

[Note that clinical summaries would be available per individual portfolio company.]